
BGI Group is a global life sciences and
genomics organisation founded in 1999 and headquartered in Shenzhen, Guangdong
Province, China. Guided by its mission, “Trans-omics for a Better Life”, BGI
integrates scientific research, technological innovation and industrial
applications to advance genomics and life sciences.
Through an integrated research, production
and application model, BGI develops and applies multi-omics technologies,
including genomics, transcriptomics, proteomics and metabolomics, across a
broad range of fields. Its activities encompass precision medicine and
healthcare, agricultural and environmental research, biodiversity conservation,
forensic science, and life sciences research. With operations and partnerships
spanning more than 100 countries and regions, BGI collaborates with
universities, research institutions, healthcare providers, public organisations
and industry partners worldwide.
BGI's ecosystem includes research
institutions, education and scientific publishing platforms, as well as
specialised businesses such as BGI Genomics (SZSE: 300676), which provides
genomic testing and precision medicine services, and MGI Tech (SSE: 688114),
which develops and manufactures genetic sequencing instruments, reagents and
related life sciences equipment. Other business areas include nutrition,
cellular technologies, forensic identification and agricultural biotechnology.
Combining large-scale research platforms,
life sciences data resources and advanced sequencing technologies, BGI seeks to
translate scientific discoveries into practical applications, support global
health and scientific innovation, and promote the development of life sciences
for the benefit of society.
华大集团成立于1999年,总部位于中国广东省深圳市,是一家以基因组学和生命科学为核心的全球性科研与产业机构。集团秉承“基因科技造福人类”的使命,以“产学研”一体化发展模式,推动基因组学、多组学技术及生命科学领域的科研创新与产业应用。
华大集团依托基因组学、转录组学、蛋白质组学、代谢组学等多组学技术平台,将前沿科研成果应用于精准医学与健康、农业与环境研究、生物多样性保护、司法鉴定及生命科学基础研究等领域。集团业务与合作网络覆盖全球100多个国家和地区,与高校、科研机构、医疗机构、公共部门及产业伙伴开展广泛合作。
集团业务生态涵盖科研机构、教育与学术出版平台,以及多个专业化产业板块。其中,华大基因(深交所:300676)主要提供基因检测、科研服务及精准医学解决方案;华大智造(上交所:688114)专注于基因测序仪器、试剂及相关生命科学设备的研发、生产与销售。此外,集团还布局营养健康、细胞技术、司法鉴定及农业生物科技等领域。
华大集团通过整合大型科研平台、生命科学数据资源与先进测序技术,推动科研成果向实际应用转化,服务全球健康、科技创新及生命科学产业发展,致力于让生命科学技术更好地惠及社会。
CCNA行动成员
华大基因获评中国网“2022年度ESG最佳社会责任企业”
2023-01-13 · 来源:华大基因
华大基因入选《中资企业在沙特阿拉伯履行社会责任报告》
2022-12-07 · 来源:华大基因